MANE · Veradermics Inc
Price
Snapshot
50 fields · last close| Market Cap | $5.31B |
| P/E | — |
| Float | 38.43M |
| Beta | 0.44 |
| Volatility | 10.9% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 57.9 |
| Price | 137.03 |
| Change | +7.80% |
| Prev Close | 127.11 |
| Open | 120.62 |
| Day Low | 113.52 |
| Day High | 130.11 |
| Avg Vol | 1 |
| Avg $ Vol | $141.7M |
| 52W High | 136.72 |
| 52W Low | 32.00 |
| 52W Pos | 100.3% |
| From High | +0.23% |
| From Low | +328.22% |
| Max DD 1Y | −24.84% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +16.23% |
| SMA 50 | +24.86% |
| SMA 200 | — |
| RSI (14) | 59.2 |
| Vol 30D | 76.4% |
| Vol 90D | 74.5% |
| 1Y Range | 32–137 |
| Daily bars | 179 |
| Perf Week | +9.33% |
| Perf Month | +12.69% |
| Perf Quarter | +15.71% |
| Perf Half Y | +73.29% |
| Perf Year | — |
| Perf YTD | +262.99% |
| Prev Day | +7.80% |
| Clavix | C |
| Debt / Eq | 0.00 |
| Curr Ratio | 16.66 |
| Int Cover | -253.7× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Low |
| Sector rank | 14 / 14 |
Clavix risk grade
regraded every trading dayMANE grades C, 57.9 of 100. Steadiest on Sector Resilience (81), most exposed on Price Stability (33, weak). 1 of the 3 weighted dimensions sit above the Pharmaceuticals median. Ranks 14 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| MANE | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.44 | 0.44 |
| Volatilityannualized | 10.9% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −24.8% | — |
| Typical daily movemedian absolute daily change | 3.04% | — |
| Days beyond ±3%of the last 178 sessions | 90 (51%) | — |
How its days are spread
Daily returns over the last 178 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MANE | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.44 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MANE | |
|---|---|
| 1 week | +9.3% |
| 1 month | +12.7% |
| Year to date | +263.0% |
| 1 year | — |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MANE | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 20 since 21 May |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 11 · 5 |
| Directionarticles whose tone is improving vs worsening | 11 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| MANE | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openVeradermics (NYSE: MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss. The trial met all endpoints and showed strong hair-growth results.
Veradermics announced positive Phase 3 results for VDPHL01, its experimental extended-release oral minoxidil pill, in a study of over 500 men with mild-to-moderate pattern hair loss. The trial showed early, consistent, and robust hair growth and is designed to support an FDA approval filing.
An analyst-style article highlights Veradermics (MANE) and its lead drug VDPHL01, a non-hormonal extended-release oral minoxidil for hair loss, which is approaching pivotal Phase 3 trial readouts and potential FDA approval. The company holds $819.9 million in cash, enough to fund operations through an anticipated 2028 commercial launch.
Veradermics (MANE) shares have climbed nearly 500% since its February 2026 IPO, driven by positive clinical trial results for its oral hair-loss treatment: it reported positive results in men in April and promising mid-stage data in women in July, potentially positioning it as the first approved pill for female-pattern hair loss.
The author says standard valuation comparison ratios, like share price relative to sales and share price relative to earnings, show the stock as stretched, while broader measures that factor in growth and profitability give mixed readings.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics Inc | B | $8.36B | — | 0.81 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| ELAN | Elanco Animal Health Inc | B | $11.34B | — | 1.75 | Compare |
| CORT | Corcept Therapeutics Inc | C | $12.59B | 228.66 | 0.52 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.88B | 14.75 | 0.37 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.80B | 43.93 | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.